MedTrace Logo

DS-5565 Phase III Study for Post-herpetic Neuralgia

NCT02318719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 765

Last updated 2020-11-02

Study results available
· View outcomes & findings →

Summary

Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo

Conditions

  • Post-Herpetic Neuralgia

Interventions

DRUG

Placebo

Placebo

DRUG

DS-5565

Sponsors & Collaborators

  • SRL Medisearch Inc.

    collaborator INDUSTRY

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Daiichi Sankyo Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daichii Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-05-25
Completion
2017-05-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02318719 on ClinicalTrials.gov